The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
Open accessAbstract
Background: The ATLAS trial compared axitinib versus placebo in patients with locoregional renal cell carcinoma (RCC) at risk of recurrence after nephrectomy. Patients and methods: In a phase III, randomized, double-blind trial, patients had >50% clear-cell RCC, had undergone nephrectomy, and had no evidence of macroscopic residual or metastatic disease [independent review committee (IRC) confirmed]. The intent-to-treat population included all randomized patients [≥pT2 and/or N+, any Fuhrman grade (FG), Eastern Cooperative Oncology Group status 0/1]. Patients (stratified by risk group/country) received (1 : 1) oral twice-daily axitinib 5 mg or placebo for ≤3 years, with a 1-year minimum unless recurrence, occurrence of second primary malignancy, significant toxicity, or consent withdrawal. The primary end point was disease-free survival (DFS) per IRC. A prespecified DFS analysis in the highest-risk subpopulation (pT3, FG ≥ 3 or pT4 and/or N+, any T, any FG) was conducted. Results: A total of 724 patients (363 versus 361, axitinib versus placebo) were randomized from 8 May 2012, to 1 July 2016. The trial was stopped due to futility at a preplanned interim analysis at 203 DFS events. There was no significant difference in DFS per IRC [hazard ratio (HR) = 0.870; 95% confidence interval (CI) : 0.660-1.147; P = 0.3211). In the highest-risk subpopulation, a 36% and 27% reduction in risk of a DFS event (HR; 95% CI) was observed per investigator (0.641; 0.468-0.879; P = 0.0051), and by IRC (0.735; 0.525-1.028; P = 0.0704), respectively. Overall survival data were not mature. Similar adverse events (AEs; 99% versus 92%) and serious AEs (19% versus 14%), but more grade 3/4 AEs (61% versus 30%) were reported for axitinib versus placebo. Conclusions: ATLAS did not meet its primary end point; however, improvement in DFS per investigator was seen in the highest-risk subpopulation. No new safety signals were reported. Trial registration number: NCT01599754.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Rini, B. I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T. E., Michaelson, M. D., Gorbunova, V. A., Gore, M. E., Rusakov, I. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61613-9 · Cited by 1,840
Self-citationJoensuu, H., Eriksson, M., Sundby Hall, K., Hartmann, J. T., Pink, D., Schütte, J., Ramadori, G., Hohenberger, P., Duyster, J., Al-Batran, S.-E., et al. (2012) · JAMA · doi:10.1001/jama.2012.347 · Cited by 980
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
Ravaud, A., Motzer, R. J., Pandha, H. S., George, D. J., Pantuck, A. J., Patel, A., Chang, Y.-H., Escudier, B., Donskov, F., Magheli, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611406 · Cited by 782
Self-citationJanzen, N. K., Kim, H. L., Figlin, R. A., & Belldegrun, A. S. (2003) · Urologic Clinics of North America · doi:10.1016/s0094-0143(03)00056-9 · Cited by 781
Haas, N. B., Manola, J., Uzzo, R. G., Flaherty, K. T., Wood, C. G., Kane, C., Jewett, M., Dutcher, J. P., Atkins, M. B., Pins, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00559-6 · Cited by 630
Houk, B. E., Bello, C. L., Poland, B., Rosen, L. S., Demetri, G. D., & Motzer, R. J. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1170-y · Cited by 477
Motzer, R. J., Agarwal, N., Beard, C., Bolger, G. B., Boston, B., Carducci, M. A., Choueiri, T. K., Figlin, R. A., Fishman, M., Hancock, S. L., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0043 · Cited by 470
Hutson, T. E., Lesovoy, V., Al-Shukri, S., Stus, V. P., Lipatov, O. N., Bair, A. H., Rosbrook, B., Chen, C., Kim, S., & Vogelzang, N. J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70465-0 · Cited by 404
Self-citationMotzer, R. J., Haas, N. B., Donskov, F., Gross-Goupil, M., Varlamov, S., Kopyltsov, E., Lee, J. L., Melichar, B., Rini, B. I., Choueiri, T. K., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.5324 · Cited by 382
Self-citation
Cited by
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
Ljungberg, B., Albiges, L., Abu-Ghanem, Y., Bensalah, K., Dabestani, S., Fernández-Pello, S., Giles, R. H., Hofmann, F., Hora, M., Kuczyk, M. A., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.02.011 · Cited by 1,456
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Chang, Y.-H., Hajek, J., Symeonides, S. N., Lee, J. L., Sarwar, N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2106391 · Cited by 785
Self-citationOverall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Symeonides, S. N., Hajek, J., Chang, Y.-H., Lee, J.-L., Sarwar, N., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312695 · Cited by 346
Self-citationPowles, T., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Symeonides, S. N., Hajek, J., Gurney, H., Chang, Y.-H., Lee, J. L., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00487-9 · Cited by 294
Self-citationYoung, M., Jackson-Spence, F., Beltran, L., Day, E., Suarez, C., Bex, A., Powles, T., & Szabados, B. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00917-6 · Cited by 271
Metadata
- Authors
- Gross-Goupil, M., Kwon, T. G., Eto, M., Ye, D., Miyake, H., Seo, S. I., Byun, S.-S., Lee, J. L., Master, V., Jin, J., DeBenedetto, R., Linke, R., Casey, M., Rosbrook, B., Lechuga, M., Valota, O., Grande, E., & Quinn, D. I.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 29
- Issue
- 12
- Pages
- 2371-2378
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2896175597
- Cited by
- 259
- References
- 17
- FWCI
- 18.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. https://app.cochat.ai/papers/10.1093/annonc/mdy454
- The paper
- Gross-Goupil, M., Kwon, T. G., Eto, M., Ye, D., Miyake, H., Seo, S. I., Byun, S.-S., Lee, J. L., Master, V., Jin, J., DeBenedetto, R., Linke, R., Casey, M., Rosbrook, B., Lechuga, M., Valota, O., Grande, E., & Quinn, D. I. (2018). Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Annals of Oncology. https://doi.org/10.1093/annonc/mdy454
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.